Want to see JP:4888 full AI Analyst Report?

STELLA PHARMA CORPORATION (4888) Price & Analysis

0 Followers

4888 Stock Chart & Stats

¥203.00

-¥14.00(-2.68%)

At close: Jan 08 4:00 PM EST

¥203.00

-¥14.00(-2.68%)

Day’s Range― - ―

52-Week Range¥200.00 - ¥995.00

Previous CloseN/A

Volume163.70K

Average Volume (3M)332.29K

Market Cap

¥11.60B

Enterprise Value¥9.93B

Total Cash (Recent Filing)¥2.82B

Total Debt (Recent Filing)¥747.14M

Price to Earnings (P/E)―

Beta0.99

Next Earnings

Aug 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-22.94

Shares Outstanding36,034,100

10 Day Avg. Volume566,500

30 Day Avg. Volume332,290

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)10.64

Price to Sales (P/S)79.85

P/FCF Ratio-74.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsSustained, very high gross margins indicate durable product-level profitability and pricing power versus peers. That margin buffer supports funding R&D and SG&A from gross profit as revenue recovers, improving odds of achieving operating leverage if top-line stabilizes.

Manageable LeverageModerate debt levels and sizable equity relative to assets reduce bankruptcy and refinancing risk compared with prior elevated leverage. This capitalization gives financial flexibility to fund development or bridge cycles without immediate distress, aiding multi‑quarter resilience.

Ability To Generate Cash In Better YearsA history of positive operating and free cash flow in 2025 demonstrates the underlying business can convert revenue to cash when operations perform, implying potential for self-funding of projects and reduced reliance on external capital in constructive operating environments.

Bears Say

Structural UnprofitabilityPersistent, deep operating and net losses and chronically negative ROE indicate the company has not reached sustainable profitability. Ongoing losses impair reinvestment capacity, increase dependency on external financing, and raise long‑term dilution or solvency risk if trends persist.

Severe Revenue VolatilityLarge, abrupt revenue swings undermine planning, impede fixed‑cost absorption, and make clinical or commercial ramp assumptions fragile. This volatility raises execution risk for product launches and reduces visibility into sustainable scale over the next several quarters.

Inconsistent Cash Generation And Recurring Cash BurnIrregular cash flow history—with several years of materially negative free cash flow—creates recurring funding needs. That pattern pressures liquidity management, can force dilutive raises or debt, and constrains long‑term R&D and commercialization investments during downturns.

4888 FAQ

What was STELLA PHARMA CORPORATION’s price range in the past 12 months?

STELLA PHARMA CORPORATION lowest stock price was ¥200.00 and its highest was ¥995.00 in the past 12 months.

What is STELLA PHARMA CORPORATION’s market cap?

STELLA PHARMA CORPORATION’s market cap is ¥11.60B.

When is STELLA PHARMA CORPORATION’s upcoming earnings report date?

STELLA PHARMA CORPORATION’s upcoming earnings report date is Aug 13, 2026 which is in 15 days.

How were STELLA PHARMA CORPORATION’s earnings last quarter?

STELLA PHARMA CORPORATION released its earnings results on May 13, 2026. The company reported -¥7.9 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.9.

Is STELLA PHARMA CORPORATION overvalued?

According to Wall Street analysts STELLA PHARMA CORPORATION’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does STELLA PHARMA CORPORATION pay dividends?

STELLA PHARMA CORPORATION does not currently pay dividends.

What is STELLA PHARMA CORPORATION’s EPS estimate?

STELLA PHARMA CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does STELLA PHARMA CORPORATION have?

STELLA PHARMA CORPORATION has 36,034,100 shares outstanding.

What happened to STELLA PHARMA CORPORATION’s price movement after its last earnings report?

STELLA PHARMA CORPORATION reported an EPS of -¥7.9 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.132%.

Which hedge fund is a major shareholder of STELLA PHARMA CORPORATION?

Currently, no hedge funds are holding shares in JP:4888

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

STELLA PHARMA CORPORATION

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.